L3VLUP
ProSign in

VIR in the 13F filings

Vir Biotechnology Inc · CUSIP 92764N102

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q4 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023
Quarter end
30 Jun 2023
the date the book describes
Filed
15 Aug 2023
latest of these filings; the earliest 28 Jul 2023
Managers listing it
5
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2023 and Q2 2023; 3 listed it in both
Shares listed
7,699,898
combined, among listed positions
Reported value
$189m
combined, at the quarter end

Managers listing VIR in Q2 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

5 of 5 holders

ActionFiling
Baillie Gifford & Co3,983,445$98m0.08%Trimmed-2,58128 Jul 2023 (the filing on sec.gov)
AllianceBernstein LP2,751,716$68munder 0.1%Added+2,87115 Aug 2023 (the filing on sec.gov)
Walleye Capital LLC863,380$21m0.08%Newnew14 Aug 2023 (the filing on sec.gov)
Woodline Partners LP81,386$2.0munder 0.1%Newnew14 Aug 2023 (the filing on sec.gov)
Winton Group Ltd19,971$490kunder 0.1%Trimmed-50,01714 Aug 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2023 to Q2 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (2)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
5 in Q2 2024 to 3 in Q2 2026

Tracked managers listing it, at least.

02462020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
VIR by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20191$6.3mn.a.n.a.
Q1 20201$4.5mn.a.n.a.
Q2 20203$223mn.a.n.a.
Q3 20202$199mn.a.n.a.
Q4 20203$189mn.a.n.a.
Q1 20213$302mn.a.n.a.
Q2 20213$292mn.a.n.a.
Q3 20213$272mn.a.n.a.
Q4 20214$375mn.a.n.a.
Q1 20223$303mn.a.n.a.
Q2 20224$176mn.a.n.a.
Q3 20224$111mn.a.n.a.
Q4 20222$102mn.a.n.a.
Q1 20234$198mn.a.n.a.
Q2 20235$189mn.a.n.a.
Q3 20232$39mn.a.n.a.
Q4 20232$43m11
Q1 20243$44m12
Q2 20245$42m41
Q3 20245$25m41
Q4 20244$14m22
Q1 20251$5.1m01
Q2 20251$4.0m00
Q4 20252$9.1m1510
Q1 20263$17m1810
Q2 20263$73m1215

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

VIR and GILD →VIR and AMGN →VIR and ARGX →Choose a stock to compare with VIR →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own VIR, latest filings →Back to the 13F Explorer →